Skip to Main Content

Content Update

July 19, 2023

Colchicine for Prevention of Cardiovascular Disease?: Recent clinical trials suggest that low-dose colchicine is a safe, cost-effective adjunct to stain therapy for secondary prevention of ASCVD. In June 2023, the FDA approved the use of low-dose colchicine (0.5 mg once daily) to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or multiple risk factors for cardiovascular disease. The many on-going and planned clinical trials will likely provide additional evidence needed to guide therapeutic recommendations and guidelines for the cardiovascular application of a drug that has been used for many years to treat non-cardiovascular inflammatory disorders.

INTRODUCTION

This chapter describes the nonsteroidal anti-inflammatory drugs (NSAIDs) used to treat inflammation, pain, and fever and the drugs used for hyperuricemia and gout. The NSAIDs are first considered by class, then by groups of chemically similar agents described in more detail. Many of the basic properties of these drugs are summarized in Tables 42–1, 42–2, and 42–3.

TABLE 42–1SOME SHARED ADVERSE EFFECTS OF NSAIDsa
TABLE 42–2NSAIDs: SALICYLATES, ACETAMINOPHEN, AND ACETIC ACID DERIVATIVES

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.